Výsledky vyhledávání - "Kelly Sussman"

Abstract 246: Application of the 3d fresh patient tumoroid platform 3d-explore to assess the immunomodulatory and phagocytic activity of the receptor tyrosine kinase inhibitor, Sunitinib

Autor: Brittany Bunch, Krithika N. Kodumudi, Jared Ehrhart, Matt Weitzman, Olivia MacIntosh, Kelly Sussman, Soner Altiok

Publikováno v: Cancer Research. 82:246-246

Background: The receptor tyrosine kinase inhibitor (TKI) Sunitinib has proven useful in the treatment of a variety of tumors. Sunitinib has shown therapeutic activity in patients with metastatic renal cell carcinoma and currently represents a frontli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d76c34ee6c199f68937e9cdb07b2cc0
https://doi.org/10.1158/1538-7445.am2022-246

Zobrazit plný text záznamu

Abstract 239: Assessment of immunotherapeutic efficacy of entinostat by using the 3d-explore ex vivo platform utilizing tumoroids of fresh patient tumor samples with intact tumor microenvironment

Autor: Krithika Nandakumar Kodumudi, Brittany Bunch, Jared Ehrhart, Matt Weitzman, Olivia MacIntosh, Kelly Sussman, Soner Altiok

Publikováno v: Cancer Research. 82:239-239

Background: Entinostat, a selective histone deacetylase 1/3 inhibitor has been shown to promote a robust anti-tumor response and increased neoantigen expression and antigen-specific T cell activation in preclinical tumor models. Entinostat plays a ro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21df93c146a2793ebe7b8edd85ddc7c0
https://doi.org/10.1158/1538-7445.am2022-239

Zobrazit plný text záznamu

Abstract 288: An ex-vivo 3D tumoroid model of fresh patient tissue (3D-EXplore) to assess transcriptional and compositional changes of the immune landscape in intact tumor microenvironment using single-cell proteogenomics

Autor: Jonathan P. Waterman-Smith, Jared Ehrhart, Brittany Bunch, Krithika Kodumudi, Matt Weitzman, Olivia MacIntosh, Kelly Sussman, Soner Altiok

Publikováno v: Cancer Research. 82:288-288

Background: Molecular changes underlying immune cell signaling in response to new therapy development are crucial to validate the clinical efficacy of immunotherapeutics. There are several preclinical tools including patient derived cell lines, organ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ee9df0df91b6d62cf7f41db99e9e240
https://doi.org/10.1158/1538-7445.am2022-288

Zobrazit plný text záznamu

586 Monitoring the impact of MDSC targeting drugs in combination with nivolumab on activation and proliferation of tumor resident effector immune cells in patient-derived 3D-EXplore platform

Autor: Kelly Guzman, Kelly Sussman, Brittany L. Bunch, Soner Altiok, Jared Ehrhart

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundMyeloid-derived suppressor cells (MDSCs) represent a diverse population of immature myeloid cells with a strong capacity to suppress the functions of NK cells and CD4+ and CD8+ T-cells in tumor immune microenvironment, thereby reducing the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96f1d27ad923b926befeb1201d188bf8
https://doi.org/10.1136/jitc-2021-sitc2021.586

Zobrazit plný text záznamu